Type 2 diabetes
Conditions
Interventions
sitagliptin
metformin
Sponsors
Divison of Diabetes and Metabolism,Itabashi Hospital, Nihon University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with type 2 daiabetes 2) Patients without change of treatment for the past three months 3) HbA1c(NGSP) 6.9%<=and10.5%> 4) Over 20 years old,Under 75 years old 5) A consent form for participating in this study is submitted 6) Possible to take the test meal (a set of Chicken in white sauce, crackers, soft pudding)
Exclusion criteria
Exclusion criteria: 1) Patients with glucagnoma 2) Patients who started in the cure for the past three months 3) Patients who changed in the cure for the past three months 4) Patients with type 1 diabetes.Patients with type 2 diabetes HbA1c>=10.5% or severe ketosis,diabetic coma. 5) Patients treated with oral hypoglycemic agents 6) Patients with nephrosic syndrome 7) Patients treated with steroid, immune-suppressive agent and azole antifungal 8) Patients with allergy against sitagliptin and metformin 9)Patients with exceeding the moderate renal impairment (sCr: male>=1.3mg/dl, female>=1.2mg/dl). 10)Patients with exceeding the moderate liver dysfunction (AST,ALT>3 times upper standard value). 11)Patients who are pregnant, breast-feeding and/or intention to become pregnant 12)Other patients determined to be inappropriate by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of glucose, glucagon and C-peptide response to MTT after sitagliptin or metformin treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of HbA1c, fasting plasma glucose, glucagon and C-peptide after sitagliptin or metforimin treatment. | — |
Countries
Japan
Outcome results
None listed